Summary
Tapinarof has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Atopic Dermatitis (Eczema) would be drug repurposing rather than first-in-human development. This does not mean it is approved for Atopic Dermatitis (Eczema). ClinicalTrials.gov lists 8 registered trials linking Tapinarof to Atopic Dermatitis (Eczema): 1 is currently recruiting; 1 is active or not yet recruiting; 6 have completed. The most advanced is Phase 4 (NCT07352566). The largest enrolment is 407 participants (NCT05014568). Registration activity spans 2008 to 2026. The literature layer holds 1 publication for this pair: 1 clinical trial publication. The dated items are from 2024. These are primary trial reports rather than syntheses, so results have not yet been pooled or graded independently.
The RepurpOS disease-intelligence file for Atopic Eczema ranks 294 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: 60-70% of childhood-onset AD achieves spontaneous remission by adolescence; adult-onset AD is more persistent; moderate-severe adult AD: <15% spontaneous clearance at 5 years.
Evidence table
| Evidence tier | A · Strong |
|---|---|
| Evidence score | 52.0 (trials 30.0, literature 2.0, tier 15, approved bonus 5.0) |
| Registered trials | 8 total: 1 recruiting, 1 active / not yet recruiting, 6 completed, 0 other |
| Linked publications | 1 (1 clinical trial publication) |
| Agent type | Drug (Small molecule) |
| Development stage (any indication) | Approved |
| Mechanism / class | agonist; agonist |
| Data sources | DGIdb |
| Linked via biomarker / target | AHR |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
| NCT ID | Title | Status | Phase | Enrolment |
|---|---|---|---|---|
| NCT07352566 | Utilization of a Microdevice for Psoriasis and Atopic Dermatitis 2026 | not yet recruiting | Phase 4 | 10 |
| NCT05014568 | Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults 2021 | completed | Phase 3 | 407 |
| NCT05032859 | Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults (DMVT-505-3102) 2021 | completed | Phase 3 | 406 |
| NCT07265479 | A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis 2025 | recruiting | Phase 3 | 180 |
| NCT02564055 | A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD) 2015 | completed | Phase 2 | 247 |
| NCT05186805 | Maximal Use Study of Tapinarof Cream, 1% in Pediatric Subjects With Extensive Atopic Dermatitis 2021 | completed | Phase 2 | 36 |
| NCT01098734 | Non-steroid, Atopic Dermatitis Phase IIb 12-week Trial; Topical WBI-1001 Cream 2009 | completed | Phase 2 | 148 |
| NCT00837551 | Phase IIa Study of WBI-1001 Cream for Atopic Dermatitis 2008 | completed | PHASE1, PHASE2 | 36 |
Published literature
- Clinical trial publication Tapinarof cream 1% once daily: Significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trialsSilverberg JI, Eichenfield LF, Hebert AA et al. · Journal of the American Academy of Dermatology · 2024 · PMID 38777187
Mechanism and notes
Recorded mechanism or class: agonist; agonist.
OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target AHR. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is Tapinarof approved for Atopic Dermatitis (Eczema)?
Tapinarof has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Atopic Dermatitis (Eczema) would be drug repurposing rather than first-in-human development. This does not mean it is approved for Atopic Dermatitis (Eczema). Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Tapinarof in clinical trials for Atopic Dermatitis (Eczema)?
ClinicalTrials.gov lists 8 registered trials linking Tapinarof to Atopic Dermatitis (Eczema): 1 is currently recruiting; 1 is active or not yet recruiting; 6 have completed. The most advanced is Phase 4 (NCT07352566). The largest enrolment is 407 participants (NCT05014568). Registration activity spans 2008 to 2026.
What does the evidence show for Tapinarof in Atopic Dermatitis (Eczema)?
Tapinarof has 6 completed trials and 1 linked publication for Atopic Dermatitis (Eczema). Completed trials may or may not have posted results; follow the NCT links to check. OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target AHR. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-05. Page built 2026-10-07.